Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities researchers at Zacks Research lowered their Q4 2025 EPS estimates for Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.37 per share for the quarter, down from their prior estimate of $2.38. The consensus estimate for Zimmer Biomet's current full-year earnings is $7.99 per share.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts' consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the company posted $1.65 EPS. The business's revenue was up 4.1% on a year-over-year basis.
Other equities research analysts have also issued reports about the stock. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating on the stock. Robert W. Baird cut their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research report on Monday, September 16th. BTIG Research dropped their price objective on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research note on Thursday, October 3rd. Finally, Royal Bank of Canada raised their target price on Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $123.22.
View Our Latest Research Report on ZBH
Zimmer Biomet Trading Up 1.2 %
ZBH stock traded up $1.38 during trading on Thursday, hitting $112.02. The company had a trading volume of 1,246,120 shares, compared to its average volume of 1,734,101. The stock has a market cap of $22.30 billion, a PE ratio of 21.30, a PEG ratio of 2.03 and a beta of 1.02. The business has a 50-day moving average of $107.18 and a 200-day moving average of $109.50. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90.
Institutional Investors Weigh In On Zimmer Biomet
A number of institutional investors and hedge funds have recently made changes to their positions in ZBH. American Century Companies Inc. raised its stake in shares of Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Boston Partners grew its holdings in Zimmer Biomet by 26.3% during the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock worth $437,413,000 after buying an additional 691,191 shares in the last quarter. Equity Investment Corp purchased a new stake in Zimmer Biomet in the 3rd quarter valued at $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock valued at $189,161,000 after acquiring an additional 577,320 shares in the last quarter. Finally, Magnetar Financial LLC boosted its holdings in Zimmer Biomet by 58.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider's stock worth $142,203,000 after acquiring an additional 484,816 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
